Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer

被引:0
作者
Hillinger, Sven [1 ]
Weder, Walter [1 ]
机构
[1] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland
来源
CONTROVERSIES IN TREATMENT OF LUNG CANCER | 2010年 / 42卷
关键词
EN-BLOC RESECTION; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; RADIOTHERAPY; SURGERY; CHEMORADIATION; SURVIVAL; OUTCOMES;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:115 / 121
页数:7
相关论文
共 23 条
[21]   Preoperative chemotherapy for lung cancer does not increase surgical morbidity [J].
Siegenthaler, MP ;
Pisters, KM ;
Merriman, KW ;
Roth, JA ;
Swisher, SG ;
Walsh, GL ;
Vaporciyan, AA ;
Smythe, WR ;
Putnam, JB .
ANNALS OF THORACIC SURGERY, 2001, 71 (04) :1105-1112
[22]   Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer [J].
Sonett, JR ;
Suntharalingam, M ;
Edelman, MJ ;
Patel, AB ;
Gamliel, Z ;
Doyle, A ;
Hausner, P ;
Krasna, M .
ANNALS OF THORACIC SURGERY, 2004, 78 (04) :1200-1206
[23]   Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer [J].
van Meerbeeck, Jan P. ;
Kramer, Gijs W. P. M. ;
Van Schil, Paul E. Y. ;
Legrand, Catherine ;
Smit, Egbert F. ;
Schramel, Franz ;
Tjan-Heijnen, Vivianne C. ;
Biesma, Bonne ;
Debruyne, Channa ;
van Zandwijk, Nico ;
Splinter, Ted A. W. ;
Giaccone, Giuseppe .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (06) :442-450